News
Clinical trials to begin on potent angiogenesis inhibitors
BMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7142.1407 (Published 09 May 1998) Cite this as: BMJ 1998;316:1407
- Kamran Abbasi
- BMJ
Two new drugs that inhibit the blood supply to tumours are to undergo clinical trials in humans. A statement by the US National Cancer Institute that research on endostatin and angiostatin is “a high priority” sent the share price of the manufacturer of the drugs, Entremed, soaring and caused massive public interest.
In one day …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.